Clinical Trial Update: Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing the lipid-lowering effects of Rosuvastatin to Atorvastatin in patients with Coronary Heart Disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• Rosuvastatin (rosuvastatin)
• atorvastatin (atorvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Coronary Heart Disease | Phase 4 | Status: COMPLETED